Predictors of subjective and objective quality of life in outpatients with schizophrenia

Psychiatry and Clinical Neurosciences

Volumn 62, Issue 4, 2008, Pages 404-411

  Yamauchi, Ken ^a   Aki, Hirofumi ^a   Tomotake, Masahito ^a   Iga, Jun Ichi ^a   Numata, Syusuke ^a   Motoki, Ikuyo ^a   Izaki, Yumiko ^a   Tayoshi, Shinya ^a   Kinouchi, Sawako ^a   Sumitani, Satsuki ^a   Tayoshi, Sumiko ^a   Takikawa, Yumiko ^a   Kaneda, Yasuhiro ^a   Taniguchi, Takahide ^a   Ishimoto, Yasuhito ^a   Ueno, Syu Ichi ^a   Ohmori, Tetsuro ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Cognitive dysfunction; Depressive and negative symptoms; Objective quality of life; Schizophrenia; Subjective quality of life

Indexed keywords

CHLORPROMAZINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CLINICAL FEATURE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; EMOTIONAL DISORDER; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HOSTILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PREDICTION; QUALITY OF LIFE; REGRESSION ANALYSIS; SCHIZOPHRENIA;

ADULT; AFFECTIVE SYMPTOMS; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTIVATION; PSYCHIATRIC STATUS RATING SCALES; QUALITY OF LIFE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL ADJUSTMENT;

EID: 48549085820     PISSN: 13231316     EISSN: 14401819     Source Type: Journal    
DOI: 10.1111/j.1440-1819.2008.01818.x     Document Type: Article

References (44)

1. Awad AG, Voruganti LN, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: Description and preliminary clinical validation. Qual. Life Res. 1997 6 : 21 26.
2. Lehman AF. A quality of life interview for the chronically mentally ill. Eval. Program Plann. 1998 11 : 51 62.
3. Meltzer HY. Dimensions of outcome with clozapine. Br. J. Psychiatry Suppl. 1992 17 (Suppl. 17 46 53.
4. Meltzer HY. Outcome in schizophrenia: Beyond symptom reduction. J. Clin. Psychiatry 1999 60 : 3 7.
5. Voruganti L, Heslegrave R, Awad AG et al. Quality of life measurement in schizophrenia: Reconciling the quest for subjectivity with the question of reliability. Psychol. Med. 1998 28 : 165 172.
6. Dickerson FB, Ringel NB, Parente F. Subjective quality of life in out-patients with schizophrenia: Clinical and utilization correlates. Acta Psychiatr. Scand. 1998 98 : 124 127.
7. Fitzgerald PB, Williams CL, Corteling N et al. Subject and observer-rated quality of life in schizophrenia. Acta Psychiatr. Scand. 2001 103 : 387 392.
8. Huppert JD, Weiss KA, Lim R et al. Quality of life in schizophrenia: Contributions of anxiety and depression. Schizophr. Res. 2001 51 : 171 180.
9. Reine G, Lancon C, Di Tucci S et al. Depression and subjective quality of life in chronic phase schizophrenic patients. Acta Psychiatr. Scand. 2003 108 : 297 303.
10. Tomotake M, Kaneda Y, Iga J et al. Subjective and objective measures of quality of life have different predictors for people with schizophrenia. Psychol. Rep. 2006 99 : 477 487.
11. Aki H, Tomotake M, Kaneda Y et al. Subjective and objective quality of life, levels of life skills, and their clinical determinants in outpatients with schizophrenia. Psychiatry Res. 2008 158 : 19 25.
12. Norman RMG, Malla AK, Mclean T et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr. Scand. 2000 102 : 303 309.
13. Strejilevich SA, Palatnik A, Avila R et al. Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics. Psychiatry Res. 2005 133 : 277 280.
14. Browne S, Roe M, Lane A et al. Quality of life in schizophrenia: Relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr. Scand. 1996 94 : 118 124.
15. Browne S, Garavan J, Gervin M et al. Quality of life in schizophrenia: Insight and subjective response to neuroleptics. J. Nerv. Ment. Dis. 1998 186 : 74 78.
16. Caron J, Mercier C, Diaz P et al. Socio-demographic and clinical predictors of quality of life in patients with schizophrenia or schizo-affective disorder. Psychiatry Res. 2005 137 : 203 213.
17. Voruganti L, Cortese L, Oyewumi L et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr. Res. 2000 16 : 135 145.
18. Davis JM, Chen N, Glick ID et al. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 2003 60 : 553 564.
19. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am. J. Psychiatry 1996 153 : 321 330.
20. Breier A, Schreiber JL, Dyer J et al. National Institute of Mental Health longitudinal study of chronic schizophrenia: Prognosis and predictors of outcome. Arch. Gen. Psychiatry 1991 48 : 239 246.
21. Ho BC, Nopoulos P, Flaum M et al. Two-year outcome in first-episode schizophrenia: Predictive value of symptoms for quality of life. Am. J. Psychiatry 1998 155 : 1196 1201.
22. Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 1999 25 : 233 255.
23. Meltzer HY, Thompson PA, Lee MA et al. Neuropsychologic deficits in schizophrenia: Relation to social function and effect of antipsychotic drug treatment. Neuropsychopharmacology 1996 14 (Suppl. 3 S27 S33.
24. Velligan DI, Mahurin RK, Diamond PL et al. The functional significance of symptomatology and cognitive function in schizophrenia. Schizophr. Res. 1997 25 : 21 31.
25. Heaton RK, Chelune GJ, Lehman RA. Using neuropsychological and personality tests to assess the likelihood of patient employment. J. Nerv. Ment. Dis. 1978 166 : 408 416.
26. McGurk SR, Meltzer HY. The role of cognition in vocational functioning in schizophrenia. Schizophr. Res. 2000 45 : 175 184.
27. Wilkinson G, Hesdon B, Wild D et al. Self-report quality of life measure for people with schizophrenia: The SQLS. Br. J. Psychiatry 2000 177 : 42 46.
28. Kaneda Y, Fujii A, Ohmori T. Schizophrenia Quality of Life Scale: Validation of the Japanese version. Psychiatry Res. 2002 113 : 107 113.
29. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: An instrument for rating the schizophrenic deficit syndrome. Schizophr. Bull. 1984 10 : 388 398.
30. Heinrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale. Seiwa Pub., Tokyo, 2001.
31. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987 13 : 261 276.
32. Bell MD, Lysaker PH, Beam-Goulet JL. Five-component model of schizophrenia: Assessing the factorial invariance of the positive and negative syndrome scale. Psychiatry Res. 1994 52 : 295 303.
33. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Press, Washington, DC, 1994.
34. Inada T. Evaluation and Diagnosis of Drug-Induced Extrapyramidal Symptoms: Commentary on the DIEPSS and Guide to Its Usage. Seiwa Pub, Tokyo, 1996 (in Japanese).
35. Kaneda Y, Fujii A, Ohmori T. Psychometric properties of the Japanese version of the Calgary Depression Scale for Schizophrenics. J. Nerv. Ment. Dis. 2000 188 : 237 239.
36. Inagaki A, Inada T. Dose equivalence of psychotropic drugs. Part 4. Dose equivalence of novel antipsychotics: Aripiprazole. Jpn. J. Clin. Psychopharmacol. 2006 9 : 249 258 (in Japanese).
37. Ritsner M, Modai I, Endicott J. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J. Clin. Psychiatry 2000 61 : 880 889.
38. Bell MD, Lysaker PH, Milstein RM et al. Concurrent validity of the cognitive component of schizophrenia: Relationship of PANSS scores to neuropsychological assessments. Psychiatry Res. 1994 54 : 51 58.
39. Hofer A, Rettenbacher MA, Widschwendter CG et al. Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2006 256 : 246 255.
40. Hofer A, Niedermayer B, Kemmler G et al. Cognitive impairment in schizophrenia: Clinical ratings are not a suitable alternative to neuropsychological testing. Schizophr. Res. 2006 92 : 126 131.
41. Keefe RSE, Goldberg TE, Harvey PD et al. The Brief Assessment of Cognition in Schizophrenia: Reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr. Res. 2004 68 : 283 297.
42. Karow A, Moritz S, Lambert M et al. PANSS syndromes and quality of life in schizophrenia. Psychopathology 2005 38 : 320 326.
43. Taniguchi T, Sumitani S, Aono M et al. Effect of antipsychotic replacement with quetiapine on the symptoms and quality of life of schizophrenic patients with extrapyramidal symptoms. Hum. Psychopharmacol. 2006 21 : 439 445.
44. Jones PB, Barnes TR, Davies L et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry 2006 63 : 1079 1087.